鼓室内地塞米松预防顺铂耳毒性的随机对照IIIB期试验
该随机对照IIIB期试验评估长期高剂量鼓室内地塞米松对顺铂化疗患者听力保护作用。结论为鼓室内地塞米松未能预防顺铂诱导的听力损失。
要点
- 长期高剂量鼓室内地塞米松未预防顺铂诱导听力损失
- 部分频率听阈差异有统计学意义但无临床显著性
- 装置相关感染8.69%、6个月永久性穿孔34.8%
核心结论
- 长期高剂量鼓室内地塞米松治疗未能预防顺铂诱导的听力损失。
研究设计与样本
- 随机对照IIIB期临床试验,同侧耳治疗、对侧耳对照,治疗耳由计算机系统随机选择。
- 受试者为肿瘤疾病且治疗方案包含顺铂的患者;顺铂平均剂量444.87 mg(SD 235.2 mg)。
- 从顺铂治疗开始至末次周期后3周,经Microwick被动扩散装置鼓室内给地塞米松(8 mg/24 h剂量)。
- 每周期顺铂前用纯音测听评估听阈。
主要发现
- 治疗完成时治疗组听阈高于对照组,500、1000、6000 Hz差异有统计学意义:4.9 dB(1.1至8.7)、5.5 dB(0.8至10.3)、16 dB(3.2至28.7),p<0.05,95%CI。
- 上述差异按ASHA听力损失标准无临床显著性。
- 治疗期间感染并发症8.69%,装置取出后6个月永久性穿孔34.8%。
关键数值与推荐
- 听阈差异在500、1000、6000 Hz有统计学意义但未达ASHA听力损失临床显著标准。
临床怎么用
- 不推荐以长期高剂量鼓室内地塞米松作为顺铂化疗患者听力损失的预防措施。
- 使用鼓室内装置需权衡感染(8.69%)和永久性穿孔(34.8%)风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the efficacy of long-term high-dose intratympanic dexamethasone in protecting the hearing capacity of cancer patients undergoing cisplatin-based ototoxic treatment. DESIGN: A randomized controlled phase IIIB clinical trial to evaluate the efficacy of dexamethasone in protecting against hearing loss in patients undergoing cisplatin treatment. The subjects participating in the clinical trial were patients with a neoplastic disease whose treatment protocol included cisplatin. The average dose of cisplatin was 444.87 mg (SD 235.2 mg). Treatment consisted of intratympanically administering dexamethasone via a passive diffusion device called Microwick (8 mg/24 h dose) from the start of treatment with cisplatin to 3 weeks after the last cycle. Patients were administered the medication to one ear, and the contralateral ear was used as the control. The treated ears were randomly chosen using a computer system (randomization). The hearing threshold was evaluated using pure tone audiometry before each cisplatin cycle. RESULTS: Thirty-four patients were recruited over a 2-year period at a reference tertiary hospital, of whom 11 were excluded. Forty-six ears were analyzed (23 treated and 23 control ears). When treatment was completed, the audiometric analysis showed a higher hearing threshold in the study group than in the control group. Differences were statistically significant at frequencies of 500, 1000, and 6000 Hz: 4.9 dB (1.1 to 8.7), 5.5 dB (0.8 to 10.3), and 16 dB (3.2 to 28.7), respectively, (p < 0.05, 95% confidence interval), but were not clinically significant according to the ASHA hearing loss criteria. Both 8.69% infection complications during treatment and 34.8% permanent perforation at 6 mo were detected after device removal. CONCLUSIONS: Long-term high-dose intratympanic dexamethasone treatment did not prevent cisplatin-induced hearing loss.
引用
- Moreno I, Belinchon A. Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial. Ear Hear. 2022. PMID: 34483247. doi:10.1097/AUD.0000000000001119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。